Who are MediCabilis CBD Oil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Marinol, Cesamet, dl-Methylphenidate plus Cannabidiol, Cannabis Sativa Oil, Cannabis Extract Oil SR Capsule, Cesamet™ (nabilone).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/medicabilis-cbd-oil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

MediCabilis CBD Oil — Competitive Intelligence Brief

MediCabilis CBD Oil (MediCabilis CBD Oil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cannabinoid. Area: Neurology, Pain Management, Psychiatry.

marketed Cannabinoid CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets) Neurology, Pain Management, Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

MediCabilis CBD Oil (MediCabilis CBD Oil) — Gold Coast Hospital and Health Service. CBD (cannabidiol) modulates endocannabinoid system signaling and interacts with multiple receptors to produce anti-inflammatory, anxiolytic, and analgesic effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MediCabilis CBD Oil TARGET	MediCabilis CBD Oil	Gold Coast Hospital and Health Service	marketed	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)
Marinol	DRONABINOL	Wellhouse Pharma	marketed	Cannabinoid [EPC]	Cannabinoid receptors	1985-01-01
Cesamet	NABILONE	Bausch Health	marketed	Cannabinoid [EPC]	Cannabinoid receptor 1	1985-01-01
dl-Methylphenidate plus Cannabidiol	dl-Methylphenidate plus Cannabidiol	University of Florida	marketed	Combination therapy: sympathomimetic amine plus phytocannabinoid	Dopamine transporter, norepinephrine transporter (methylphenidate); CB1/CB2 receptors, 5-HT1A, TRPV1 (cannabidiol)
Cannabis Sativa Oil	Cannabis Sativa Oil	Fondation pour l'accueil et l'hébérement des personnes âgées	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor
Cannabis Extract Oil SR Capsule	Cannabis Extract Oil SR Capsule	University of Sao Paulo General Hospital	marketed	Cannabinoid receptor modulator	CB1 receptor, CB2 receptor
Cesamet™ (nabilone)	Cesamet™ (nabilone)	NEMA Research, Inc.	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cannabinoid class)

Wayne State University · 3 drugs in this class
Hôpital le Vinatier · 1 drug in this class
Montefiore Medical Center · 1 drug in this class
OMNI Medical Services, LLC · 1 drug in this class
Gold Coast Hospital and Health Service · 1 drug in this class
Stero Biotechs Ltd. · 1 drug in this class
University of California, San Diego · 1 drug in this class
University of Connecticut · 1 drug in this class
Staci Gruber, Ph.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MediCabilis CBD Oil — Competitive Intelligence Brief. https://druglandscape.com/ci/medicabilis-cbd-oil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab